Literature DB >> 9661647

Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I.

E S Kurland1, F K Chan, C J Rosen, J P Bilezikian.   

Abstract

Many men with idiopathic osteoporosis have reduced circulating insulin-like growth factor-I (IGF-I) levels. The major source of circulating IGF-I is GH-mediated production by the liver. The known anabolic effects of GH on the skeleton raised the possibility of GH deficiency in these men. We sought to test this hypothesis in this study. Fourteen men (mean age, 52.1 +/- 3.2 yr, range 31-68) with idiopathic osteoporosis were studied. Mean lumbar spine bone mineral density (BMD) was 0.723 g/cm2, T score -3.5; femoral neck BMD was 0.642 g/cm2, T score, -3.07; distal (1/3) radius BMD was 0.708 g/cm2, T score, -2.05. Eleven of 14 (79%) had frank reductions in serum IGF-I levels compared with age and sex-matched values (158.5 +/- 50 SD vs. 180 +/- 45 SD). GH secretion was stimulated by iv arginine infusion (30 g) over 30 min followed 1 h later by oral L-dopa (500 mg). Serum GH was measured at time (t) = -15, 0, 30, 45, 60, 90, 120, 150, and 180 min. All patients responded to at least one stimulus with the majority (n = 9) responding to both. Five patients responded either to arginine or to L-dopa but not to both. Baseline GH for the entire group was 0.77 + 0.08 ng/mL (SEM). Peak GH following arginine (t = 45-60 min) was 14.0 +/- 2.8 ng/mL, a 17.7 +/- 2.8-fold rise. Peak GH following L-dopa (t = 120-180 min) was 5.7 +/- 1.0 ng/mL, a 9.2 +/- 2.2-fold rise. No difference in maximal secretion was observed between those with low or normal IGF-I levels. Neither IGF-I nor IGF binding protein-3 concentrations changed significantly during the short period of GH stimulation. These data suggest that men with osteoporosis and reduced IGF-I levels do not appear to have a deficiency in the GH axis. Other hormonal or local factors may be important in regulating IGF-I expression. Deficiencies of IGF-I production at skeletal sites may be important in the pathogenesis of this syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661647     DOI: 10.1210/jcem.83.7.4971

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  Male osteoporosis: new trends in diagnosis and therapy.

Authors:  Hosam K Kamel
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  A single nucleotide polymorphism in osteonectin 3' untranslated region regulates bone volume and is targeted by miR-433.

Authors:  Neha S Dole; Kristina Kapinas; Catherine B Kessler; Siu-Pok Yee; Douglas J Adams; Renata C Pereira; Anne M Delany
Journal:  J Bone Miner Res       Date:  2015-04       Impact factor: 6.741

Review 4.  Insulin-Like growth factor I: implications in aging.

Authors:  E Arvat; F Broglio; E Ghigo
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 5.  Idiopathic osteoporosis in men.

Authors:  Luigi Gennari; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 6.  Osteoporosis in men: pathophysiology and treatment.

Authors:  Luigi Gennari; John P Bilezikian
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

7.  Osteoporosis in men: pathophysiology and treatment.

Authors:  Luigi Gennari; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2007-03       Impact factor: 5.096

Review 8.  Unresolved issues in osteoporosis in men.

Authors:  E Seeman
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 9.  Osteoporosis in men.

Authors:  Sundeep Khosla; Shreyasee Amin; Eric Orwoll
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

10.  Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis.

Authors:  A M Delany; D J McMahon; J S Powell; D A Greenberg; E S Kurland
Journal:  Osteoporos Int       Date:  2007-12-15       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.